Previous issue | Volume 98 | ESPE2024

62nd Annual ESPE (ESPE 2024)

Liverpool, UK
16 Nov 2024 - 18 Nov 2024

Card image cap
The 62nd ESPE Annual Meeting will now be taking place in Liverpool, UK.

Free Communications

Fat, Metabolism and Obesity 1

hrp0098fc6.1 | Fat, Metabolism and Obesity 1 | ESPE2024

Corneal Nerve Loss and regeneration after GLP-1 Therapy in Children with Simple and Monogenic Obesity

Gad Hoda , Dauleh Hajar , Chirayath Shiga , Amin Rasha , Mohamadsalih Ghassan , Pasha Maheen , Mohammed Idris , Al-Barazenji Tara , Khalifa Amel , Petrovski Goran , Hamdoun Elwaseila , Al Bureshad Khalid , Ibrahim Marwa , A. Malik Rayaz , Hussain Khalid

Background: Obesity is highly prevalent in the MENA region, especially in children and it has been associated with neurodegeneration. We have undertaken corneal confocal microscopy (CCM) to assess for evidence of neurodegeneration in children with simple obesity and monogenic obesity (MC4R gene mutation) and further assessed the effect of glucagon-like peptide 1 agonist (GLP-1) therapy on corneal nerve regeneration.Methods:</stro...

hrp0098fc6.2 | Fat, Metabolism and Obesity 1 | ESPE2024

Frequency of Bardet-Biedl syndrome variants in a population with early-onset obesity

Argente Jesús , Rosaria Umano Giuseppina , Yildiz Melek , Carmon Lior , Sleiman Patrick , Savoie Charles , le Roux Carel , Goldstone Anthony

Introduction: The melanocortin-4 receptor (MC4R) pathway is critical for hunger regulation, energy balance, and weight regulation. In patients with Bardet–Biedl syndrome (BBS), a rare, genetically heterogeneous, and highly pleiotropic disease, the immotile primary cilia are dysfunctional, leading to MC4R pathway impairment. Patients suffer from symptoms including early vision loss, learning difficulties, and renal dysfunction, next to hyperphagia and ear...

hrp0098fc6.3 | Fat, Metabolism and Obesity 1 | ESPE2024

SPISE is more strongly correlated with cardiometabolic factors in adolescents with obesity than HOMA-IR, and is related to the amount of body weight reduction under lifestyle intervention

Tantari Giacomo , Brandt-Heunemann Stephanie , Maghnie Mohamad , Siegfried Wolfgang , Denzer Christian , Wabitsch Martin

Introduction: Impaired insulin sensitivity (IS) is a hallmark of increased cardiometabolic risk in adolescents with obesity. Surrogate markers of IS based on fasting insulin have important limitations. The Single-Point Insulin Sensitivity Estimator-Index (SPISE), obtained using the mathematical formula 600 × HDL-C^0.185/Triglycerides^0.2 × BMI^1.338, has been shown to be a predictor for detecting both insulin resistance and the risk of developing g...

hrp0098fc6.4 | Fat, Metabolism and Obesity 1 | ESPE2024

Relaxation of Food Control Parameters Based on Improvements in the Food Safe Zone Questionnaire Occurs with Reduction of Hyperphagia in Clinical Trials of Diazoxide Choline Extended Release (DCCR) in Participants with Prader-Willi Syndrome

Bridges Nicola , Gevers Evelien , Yanovski Jack , Salehi Parisa , Hall Shoemaker Ashley , Abuzzahab Jennifer , Obrynba Kathryn , Fleischman Amy , Stevenson David , Wilding John , Mathew Verghese , Viskochil David , Felner Eric , E. McCandless Shawn , Bird Lynne , Lah Melissa , Littlejohn Elizabeth , Shea Heidi , Holland Anthony , Goldstone Anthony , Barrett Timothy , Konczal Laura , Dharmaraj Poonam , Das Urmi , Angulo Moris , Kimonis Virginia , Guftar Shaikh Mohomad , Mejia-Corletto Jorge , Yen Kristen , Gandhi Raj , Ballal Shaila , Hirano Patricia , Cowen Neil , Bhatnagar Anish , Huang Michael , Butler Merlin , Miller Jennifer

Background: Prader-Willi syndrome (PWS) is a rare genetic neurobehavioral-metabolic disorder characterized by hyperphagia and behavioral/psychological complications. With no approved therapies to treat hyperphagia, disease management requires strict dietary and environmental controls to restrict access to food. DCCR is an oral, once-daily medication currently under development for the treatment of PWS.Objective: The obje...

hrp0098fc6.5 | Fat, Metabolism and Obesity 1 | ESPE2024

First cross sectional analysis of the eclip registry

von Schnurbein Julia , Nagel Gabriele , Akinci Baris , Broekma Marjoleine , Csajbok Eva , Rosaria D'Apice Maria , Gambineri Alessandra , Heldt Kathrin , Kleinendorst Lotte , Lattanzi Giovanna , Miehle Konstanze , Prodami Flavia , Santini Ferruccio , Santos Silva Ermelinda , B Savage David , Scherer Thomas , Sbraccia Paolo , Sorkina Ekaterina , Štotl Iztok , Vantyghem Marie-Christine , Vigouroux Corinne , Vorona Elena , Araújo-Vilar David , Wabitsch Martin , Vatier Camille , Ceccarini Giovanni

Background: Lipodystrophy syndromes comprise a group of extremely rare and heterogeneous diseases characterized by a selective loss of adipose tissue in the absence of nutritional deprivation or catabolic state. Because of the rarity of each lipodystrophy sub-form, research in this area requires international co-operation. Therefore, in 2016, the European Consortium of Lipodystrophies (ECLip) decided to create a registry for patients affected by lipodystrophy....

hrp0098fc6.6 | Fat, Metabolism and Obesity 1 | ESPE2024

Novel Melanocortin and Gut-peptide Dual Agonist for Obesity and Diabetes Treatment

Elfers Clinton , Chichura Kylie , Ashlaw Emily , Mullins Ginger , Chavez Miranda Isabella , Doyle Robert , Roth Christian

Background: While research demonstrated successful weight and BMI reduction in response to recent obesity drugs in adults and adolescents, there are significant limitations of current drugs targeting single receptors, such as problems maintaining a reduced weight status, and the high rates of gastrointestinal adverse events, which can lead to discontinuation of treatment. Based on this, we hypothesized that a more effective and better tolerated obesity interve...